UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 29, 2015
ABAKAN INC.
(Exact name of registrant as specified in its charter)
Nevada
000-52784
98-0507522
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
2665 S. Bayshore Drive, Suite 450, Miami, Florida 33133
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code: (786) 206-5368
n/a
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:
□
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
□
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM 5.02
DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF
DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS
(b)
Effective May 29, 2015, the board of directors of Abakan Inc. (the “Company”) terminated
Costas Takkas as its chief financial officer and principal accounting officer.
(c)
Effective May 29, 2015, the board of directors appointed Robert H. Miller as its chief financial
officer and principal accounting officer. Mr. Miller is sixty two (62) years old.
Mr. Miller brings to his new position seasoned management skills and a keen familiarity with accounting
requirements having over 30 years of investment experience in several business ventures. He has also
served as the Company’s chief executive officer and as a director since December 8, 2009, earning him a
comprehensive familiarity with its business activities. Mr. Miller served as a director and officer of
Sonnen Corporation, a company once involved in the research and development of a novel process for
energy generation consisting of specific materials and proprietary material combinations from June 16,
2009, and July 27, 2009, respectively until May 1, 2014. Since 2007, Mr. Miller has served as a director
of Lifespan Biosciences Inc., a company commercializing proprietary antibodies, providing immune
histochemistry services and developing localization databases.
Mr. Miller has a consulting agreement with the Company in connection with the services he renders as an
executive officer. The compensatory terms of the consulting agreement are comprised solely of a base
salary. However, the Company does intend to enter into an employment agreement with Mr. Miller to
reflect his position as chief executive officer, chief financial officer and principal accounting officer. The
compensatory terms of any new employment agreement would most likely be comprised of a base salary,
options to purchase shares of the Company’s common stock, and a retention award, in addition to health,
disability and life benefits.
Mr. Miller has not entered into any arrangement or understanding with any other persons in connection
with his appointment as the Company’s chief financial officer and principal accounting officer.
Mr. Miller is not related to any director, executive officer or person nominated or chosen by the Company
to become a director or executive officer.
Since the beginning of its last fiscal year, Mr. Miller has not entered into a related transaction with the
Company in connection with his service as an officer and director.
_____________________________________________________________________________________
ITEM 7.01
REGULATION FD DISCLOSURE
The Company has made available on its website at www.abakaninc.com/presentations.html a press
release titled Abakan Announces Interim CFO, dated May 28, 2015, in connection with the appointment
of a new chief financial and principal accounting officer.
The Company is furnishing said information in this Current Report on Form 8-K and in Exhibit 99.1 to
comply with Regulation FD. Such information shall not be deemed to be “filed” for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings
under the Securities Act of 1933, as amended or the Securities and Exchange Act of 1934, as amended
whether made before or after the date hereof and regardless of any general incorporation language in such
filings, except to the extent expressly set forth by specific reference in such filing.
________________________________________________________________________________
ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS
_____________________________________________________________________________________
(d)
Exhibits
The exhibits required to be attached by Item 601 of Regulation S-K are filed herewith.
Exhibit No.
Page No.
Description
99.1
Attached
Press Release dated May 28, 2015
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
Abakan Inc.
Date
By: /s/ Robert H. Miller
June 1, 2015
Name: Robert H. Miller
Title: Chief Executive Officer
